SB656933: Clinical Trials

2 trials of SB656933, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Terminated 1

Follow SB656933: new trials by email Literature Review of SB656933 trials Research Report on SB656933

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
28 Day Repeat Dose in Cystic Fibrosis Patients
SB656933, Placebo - Cystic Fibrosis
Phase 2CompletedGlaxoSmithKline1462009-09-282017-11-17
Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis
SB-656933 - Colitis, Ulcerative
Phase 2TerminatedGlaxoSmithKline32009-01-222020-10-30

Conditions studied

Colitis, Ulcerative (1)  ·  Cystic Fibrosis (1)

Sponsors

GlaxoSmithKline (2)

Countries

Canada (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Netherlands (1)  ·  United States (1)

Results publications

PMID 22995323